Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.68 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.67 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.64 |
| ▸ | PPARG | P37231 | 7/20 | 0.64 |
| ▸ | PPARD | Q03181 | 7/20 | 0.64 |
| ▸ | PPARA | Q07869 | 7/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.64 |
| ▸ | FABP4 | P15090 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TLR2 | O60603 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL8374060 | 0.97 | GPR84 (0.68) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL7952938 | 0.92 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL7471228 | 0.92 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL4523506 | 0.92 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL2807771 | 0.92 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL23014527 | 0.92 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL7947676 | 0.92 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL7462002 | 0.92 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL59956 | 0.92 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL4229756 | 0.92 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706123-A4 | COMPOSITIONS DERIVED FROM PORTULACA OLERACEA L. AND METHODS OF USING SAME FOR MODULATING BLOOD GLUCOSE LEVELS | HERB LTD D (IL) | 2009-07-15 | — | — | EP | claimed |
| US-20070154572-A1 | Compositions derived from portulaca oleracea l. and methods of using same for modulating blood glucose levels | D-HERB LTD. (IL) | 2007-07-05 | — | — | US | claimed |
| EP-1706123-A2 | COMPOSITIONS DERIVED FROM PORTULACA OLERACEA L. AND METHODS OF USING SAME FOR MODULATING BLOOD GLUCOSE LEVELS | D-Herb Ltd. (IL) | 2006-10-04 | — | — | EP | claimed |
| WO-2005060349-A2 | COMPOSITIONS DERIVED FROM PORTULACA OLERACEA L. AND METHODS OF USING SAME FOR MODULATING BLOOD GLUCOSE LEVELS | D-HERB LTD. (IL) | 2005-07-07 | — | — | WO | claimed |
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2020-09-29 | — | — | US | disclosed |
| EP-3429997-A1 | N-(CYANOBENZYL)-6-(CYCLOPROPYL-CARBONYLAMINO)-4-(PHENYL)-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PESTICIDES AND PLANT PROTECTION AGENTS | Bayer CropScience Aktiengesellschaft (DE) | 2019-01-23 | — | — | EP | disclosed |
| US-10077225-B2 | Synthesis of intermediate for treprostinil production | UNITED THERAPEUTICS CORPORATION (US) | 2018-09-18 | — | — | US | disclosed |
| WO-2017157885-A1 | N-(CYANOBENZYL)-6-(CYCLOPROPYL-CARBONYLAMINO)-4-(PHENYL)-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PESTICIDES AND PLANT PROTECTION AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | WO | disclosed |
| US-20170197898-A1 | SYNTHESIS OF INTERMEDIATE FOR TREPROSTINIL PRODUCTION | UNITED THERAPEUTICS CORPORATION (US) | 2017-07-13 | — | — | US | disclosed |
| US-9611206-B2 | Synthesis of intermediate for treprostinil production | UNITED THERAPEUTICS CORPORATION (US) | 2017-04-04 | — | — | US | disclosed |
| EP-3056198-A2 | USE OF COMPOUNDS FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS TO CHONDROCYTES | MSP Co., Ltd (KR) | 2016-08-17 | — | — | EP | disclosed |
| EP-2617415-B1 | USE OF A COMPOUND FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARTILAGE CELLS | CATHOLIC KWANDONG UNIVERSITY INDUSTRY FOUNDATION (KR) | 2016-04-20 | — | — | EP | disclosed |
| US-5405851-A | Administering benzoquinazoline thymidylate synthase inhibitors | BURROUGHS WELLCOME CO. (US) | 1995-04-11 | — | — | US | disclosed |
| EP-0342664-B1 | 2,2-disubstituted benzopyran leukotriene-D4 antagonists | SEARLE & CO (US) | 1993-12-15 | — | — | EP | disclosed |
| US-5219883-A | 2,2-di-substituted benzopyran leukotriene-D4 antagonists | G. D. SEARLE & CO. (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0535034-A1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-04-07 | — | — | EP | disclosed |
| US-5093353-A | 2,2-di-substituted benzopyran leukotriene-D4 antagonists | G. D. SEARLE & CO. (US) | 1992-03-03 | — | — | US | disclosed |
| WO-1991019700-A1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-26 | — | — | WO | disclosed |
| US-4950684-A | 2,2-di-substituted benzopyran leukotriene-D4 antagonists | G. D. SEARLE & CO. (US) | 1990-08-21 | — | — | US | disclosed |
| EP-0342664-A2 | 2,2-disubstituted benzopyran leukotriene-D4 antagonists | G.D. Searle & Co. (US) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070154572-A1 | Compositions derived from portulaca oleracea l. and methods of using same for modulating blood glucose levels | PNLIP, LIPC, SLC5A1 | FFAR3 2028/4885HDAC3 3358/4885HDAC1 1278/4885 |
| US-10077225-B2 | Synthesis of intermediate for treprostinil production | PTGIS, PTGES, TBXAS1 | FFAR3 866/4885HDAC3 1968/4885HDAC1 1635/4885 |
| US-20170197898-A1 | SYNTHESIS OF INTERMEDIATE FOR TREPROSTINIL PRODUCTION | PTGIS, PTGES, TBXAS1 | FFAR3 866/4885HDAC3 1968/4885HDAC1 1635/4885 |
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | DNA2, IRF3, DDB1 | FFAR3 2800/4885HDAC3 1785/4885HDAC1 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.